Azerbaijan vs Sri Lanka: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Azerbaijan
0.3%
in 2024
Sri Lanka
0.3%
in 2024
Azerbaijan rank
85th
Sri Lanka rank
85th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Azerbaijan
- Sri Lanka
How they compare
Azerbaijan currently reports 0.3% against 0.3% in Sri Lanka, a difference of 0.0%.
Across all 10 years both countries report, Sri Lanka has been ahead every year.
Azerbaijan ranks 85th and Sri Lanka ranks 85th of 246 countries.
Sri Lanka has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Azerbaijan | Sri Lanka | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.2% | 0.3% | 0.1% | Sri Lanka |
| 2020s | 0.3% | 0.3% | 0.0% | Sri Lanka |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Azerbaijan or Sri Lanka?
- Azerbaijan, at 0.3% against 0.3% in Sri Lanka as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Azerbaijan and Sri Lanka?
- 0.0%, with Azerbaijan ahead.
- How many years of comparable data are there for Azerbaijan and Sri Lanka?
- 10 years are reported by both, from 2015 to 2024.
- How do Azerbaijan and Sri Lanka rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Azerbaijan ranks 85th and Sri Lanka ranks 85th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.